Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: June 28, 2022

LUCEMYRA Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

When do Lucemyra patents expire, and what generic alternatives are available?

Lucemyra is a drug marketed by Uswm and is included in one NDA.

The generic ingredient in LUCEMYRA is lofexidine hydrochloride. Additional details are available on the lofexidine hydrochloride profile page.

Summary for LUCEMYRA
Drug patent expirations by year for LUCEMYRA
Drug Prices for LUCEMYRA

See drug prices for LUCEMYRA

DrugPatentWatch® Estimated Generic Entry Opportunity Date for LUCEMYRA
Generic Entry Date for LUCEMYRA*:
Constraining patent/regulatory exclusivity:

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LUCEMYRA

Identify potential brand extensions & 505(b)(2) entrants

Pharmacotherapies for Alcohol and Substance Abuse ConsortiumPhase 2
Michael E. DeBakey VA Medical CenterPhase 2
United States Department of DefensePhase 2

See all LUCEMYRA clinical trials

US Patents and Regulatory Information for LUCEMYRA

LUCEMYRA is protected by zero US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of LUCEMYRA is See Plans and Pricing.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

FDA Regulatory Exclusivity protecting LUCEMYRA

Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Uswm LUCEMYRA lofexidine hydrochloride TABLET;ORAL 209229-001 May 16, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.